RenovoRx and Imugene have joined forces in a strategic research collaboration to enhance the delivery of Imugene’s oncolytic virus therapy using RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform. The collaboration aims to develop targeted combination therapies for the treatment of difficult-to-access tumours.
RenovoRx is a clinical-stage biopharmaceutical company focused on developing innovative combination therapies, while Imugene is a clinical-stage immuno-oncology company specializing in therapies that harness the body’s immune system to fight cancer.
The goal of this collaboration is to optimise the delivery of Imugene’s oncolytic virus therapy, which is designed to selectively target and destroy cancer cells while sparing healthy cells, using RenovoRx’s TAMP therapy platform. TAMP is a cutting-edge approach that allows targeted delivery of therapies directly to tumours through micro-perfusion.
By combining the strengths of both companies, the strategic research collaboration aims to develop more effective and precise treatment options for tumours that are challenging to reach through traditional means. This partnership has the potential to significantly improve patient outcomes and advance the field of immuno-oncology.
Imugene managing director and CEO Leslie Chong said: “We believe the synergy between RenovoRx’s trans-arterial drug delivery system and our CF33 oncolytic virus platform has the potential to facilitate treatment of difficult-to-access cancers and help patients.”
RenovoRx CEO Shaun Bagai said: “Our collaboration with Imugene is an important milestone for RenovoRx as we expand our pipeline from exclusively treating locally advanced disease to treating metastatic disease with immunotherapy.
“We look forward to combining our proprietary TAMP platform with Imugene’s CF33 oncolytic virus with the goal of optimising clinical benefits for patients.”
In their collaborative research efforts, Imugene and RenovoRx will explore the potential of combining Imugene’s CF33 oncolytic virus technology with RenovoRx’s TAMP therapy platform. The aim is to investigate the feasibility of administering CF33 via the TAMP platform to treat difficult-to-access tumours, such as those found in pancreatic and liver cancers. This approach may prove beneficial for cancer patients, particularly compared to traditional administration methods that face challenges in delivering therapies to tumours with dense fibrous tissue and limited blood vessel supply.
RenovoRx’s TAMP platform is specifically designed to ensure precise delivery of therapeutics to the target tissue. In a study presented at the Society of Interventional Radiology 2019 Annual Meeting, the proprietary TAMP platform demonstrated a significant 100-fold increase in local tissue concentration compared to conventional intravenous (IV) delivery.
Additionally, TAMP showed advantages over off-the-shelf intra-arterial (IA) delivery methods. By uniformly distributing the therapy in the target tissue, TAMP’s unique approach has the potential to enhance the efficacy, safety, and therapeutic range of oncology treatments.
The research collaboration between Imugene and RenovoRx holds promise for advancing treatment options for patients with difficult-to-treat tumours, offering the potential for improved outcomes and an enhanced therapeutic approach in the field of immuno-oncology.
